ANEB vs. STSA, SLGL, OPNT, OPTN, ACRV, PYXS, OMER, AKBA, RANI, and DSGN
Should you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Satsuma Pharmaceuticals (STSA), Sol-Gel Technologies (SLGL), Opiant Pharmaceuticals (OPNT), OptiNose (OPTN), Acrivon Therapeutics (ACRV), Pyxis Oncology (PYXS), Omeros (OMER), Akebia Therapeutics (AKBA), Rani Therapeutics (RANI), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical preparations" industry.
Satsuma Pharmaceuticals (NASDAQ:STSA) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.
Satsuma Pharmaceuticals received 224 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 87.50% of users gave Anebulo Pharmaceuticals an outperform vote while only 63.46% of users gave Satsuma Pharmaceuticals an outperform vote.
93.3% of Satsuma Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 31.2% of Satsuma Pharmaceuticals shares are held by insiders. Comparatively, 85.9% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Anebulo Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 207.22%. Given Satsuma Pharmaceuticals' higher probable upside, analysts plainly believe Anebulo Pharmaceuticals is more favorable than Satsuma Pharmaceuticals.
Anebulo Pharmaceuticals' return on equity of -115.24% beat Satsuma Pharmaceuticals' return on equity.
In the previous week, Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled Satsuma Pharmaceuticals'average media sentiment score.
Satsuma Pharmaceuticals has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.09, indicating that its stock price is 209% less volatile than the S&P 500.
Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Satsuma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Satsuma Pharmaceuticals and Anebulo Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get Anebulo Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anebulo Pharmaceuticals Competitors List
Related Companies and Tools
